Healthcare Analytical Testing Market By Product Type (Raw Material Testing, In-Process Testing, Finished Product Testing, Stability Testing); By Technology (Chromatography, Spectroscopy, Mass Spectrometry, PCR, Immunoassays, Others); By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Contract Manufacturing Organizations, Hospitals & Diagnostic Laboratories, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
The global healthcare analytical testing market was valued at USD 8,183 million in 2024 and is projected to reach USD 18,870.73 million by 2032, expanding at a compound annual growth rate (CAGR) of 11.01% during the forecast period, according to Credence Research. This growth reflects rising demand for regulatory-compliant analytical services across pharmaceutical, biotechnology, clinical research and advanced therapy development workflows.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Healthcare Analytical Testing Market Size 2024
USD 8,183 million
Healthcare Analytical Testing Market, CAGR
11.01%
Healthcare Analytical Testing Market Size 2032
USD 18,870.73 million
The global healthcare analytical testing market is characterized by the presence of large contract testing organizations, multinational laboratory networks and specialized bioanalytical service providers competing on scientific expertise, regulatory compliance, global reach, turnaround time and advanced testing capabilities. Leading players focus on bioanalytical testing, method development and validation, stability testing, impurity profiling and molecular diagnostics to support complex drug development pipelines. Strategic priorities across the sector include laboratory automation, expansion of global testing capacity, high-resolution analytical platforms, data integrity systems and long-term partnerships with pharmaceutical and biotechnology companies.
Strategic Market Insights
Market growth is primarily driven by expanding pharmaceutical and biopharmaceutical research activity, rising clinical trial volumes, increasing biologics development and stricter regulatory requirements for safety, efficacy, quality and product consistency.
Dominant industry trends highlight growing adoption of advanced analytical technologies, with chromatography holding the leading share due to its strong role in impurity profiling, compound separation, method validation and regulatory submission support.
The competitive landscape is defined by global laboratory networks, regulatory expertise, high-throughput bioanalytical capabilities and continued investment in automation, molecular diagnostics, liquid chromatography-mass spectrometry and digital data management systems.
Regional mapping, North America represents the largest market, accounting for a definitive 38% share due to high pharmaceutical R&D spending, strong biologics pipelines, advanced clinical trial infrastructure and stringent FDA compliance requirements.
Data compiled by Credence Research confirms that bioanalytical testing constitutes the dominant service type, holding an estimated 42% market share. This leadership reflects rising demand for pharmacokinetic studies, bioavailability testing, biomarker analysis and therapeutic monitoring across drug development stages. Pharmaceutical and biotechnology companies rely on bioanalytical services to generate validated data for clinical trials, regulatory submissions and product development decisions. Growth in biologics, biosimilars, cell therapies and complex molecules continues to increase testing complexity, strengthening demand for specialized providers with validated methods and advanced laboratory capabilities.
Method development and validation follows with a 24% share, supported by strict regulatory requirements for assay accuracy, reproducibility and analytical robustness. Stability testing accounts for 19%, driven by shelf-life studies, storage condition assessments and lifecycle quality management. Raw material and impurity testing represents the remaining share, supporting product quality, contamination control and compliance across pharmaceutical manufacturing and clinical research operations.
Eurofins Scientific operates more than 900 laboratories and runs more than 200 validated bioanalytical methods supporting pharmacokinetic and biomarker studies, reinforcing its strong position in global healthcare analytical testing services.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Credence Research identifies chromatography as the leading technology segment, accounting for approximately 39% of the global healthcare analytical testing market. Its dominance is supported by high precision, strong reproducibility and wide applicability across impurity profiling, compound separation, stability studies and regulatory documentation. Techniques such as high-performance liquid chromatography and gas chromatography are widely used in pharmaceutical quality control and drug development because they generate reliable analytical data accepted by regulatory authorities.
Spectroscopy holds a 26% share, driven by demand for compound identification, structural analysis and quality verification. Molecular diagnostics account for 21%, supported by growth in personalized medicine, genetic testing and biomarker-guided therapies. Immunoassays represent the remaining share and remain widely used for biomarker detection, high-throughput screening and clinical research applications.
Thermo Fisher Scientific Orbitrap liquid chromatography-mass spectrometry systems achieve mass resolution above 500,000 for complex impurity analysis, supporting high-precision testing needs in advanced drug development and quality control environments.
By End User
Pharmaceutical companies dominate the end user segment with an estimated 45% market share. Their leadership is driven by strong R&D spending, expanding clinical pipelines, complex regulatory requirements and rising outsourcing of analytical services to improve development efficiency. Pharmaceutical companies rely heavily on third-party laboratories for bioanalytical testing, stability studies, impurity analysis, method validation and regulatory submission support. Outsourcing allows these companies to reduce internal infrastructure pressure while accessing specialized expertise and advanced testing technologies.
Biotechnology companies hold a 27% share, supported by growth in biologics, cell-based therapies, gene therapies and precision medicine platforms. Contract research organizations account for 18%, reflecting the broader outsourcing trend across clinical trials and drug development. Academic and research institutes represent the remaining share, contributing through early-stage drug discovery, translational research and specialized analytical studies.
Key Market Dynamics
Primary Market Drivers
Rising Pharmaceutical and Biopharmaceutical R&D Activity
Growing investment in pharmaceutical and biopharmaceutical research remains a core commercial driver for the healthcare analytical testing market. Drug developers continue to expand pipelines across oncology, immunology, rare diseases, metabolic disorders and advanced therapies. These programs require validated analytical data to support preclinical studies, clinical trials and regulatory submissions. Bioanalytical testing plays a central role in pharmacokinetic evaluation, biomarker assessment and therapeutic monitoring. The growth of biologics and complex molecules increases testing complexity and strengthens reliance on specialized service providers. Credence Research identifies sustained R&D expansion as one of the strongest long-term drivers of analytical testing demand. Charles River Laboratories supported more than 4,000 active client drug development programs using validated bioanalytical assays for pharmacokinetics and biomarker studies.
Stringent Regulatory Requirements and Quality Compliance
Regulatory pressure significantly fuels demand for healthcare analytical testing services. Agencies require rigorous testing to verify safety, efficacy, purity, potency and product quality throughout the product lifecycle. Analytical data supports investigational filings, marketing approvals, manufacturing changes, batch release and post-approval monitoring. Method validation, impurity testing, stability testing and raw material analysis remain essential to regulatory compliance. Global harmonization standards are increasing testing scope and documentation requirements across markets. Manufacturers prioritize compliance to avoid delays, recalls and audit findings. Intertek Group operates a global network of laboratories and offices that provide good manufacturing practice-compliant analytical testing and regulatory-driven method validations across multiple industries.
Growth of Biologics and Personalized Medicine
The rapid expansion of biologics, biosimilars, cell therapies, gene therapies and personalized medicine is creating strong demand for advanced analytical testing. These therapies have complex molecular structures that require specialized characterization, stability assessment, potency testing and biomarker analysis. Precision medicine depends on accurate molecular diagnostics and validated biomarker platforms to support patient selection and treatment monitoring. Analytical testing also supports batch-to-batch consistency, product comparability and lifecycle quality management. This transition toward complex therapies increases demand for high-end testing services, advanced instrumentation and scientific expertise. Credence Research indicates that biologics and personalized therapies will remain major demand catalysts through 2032.
Key Trends & Structural Opportunities
Adoption of Advanced Analytical Technologies
Technology innovation is reshaping the healthcare analytical testing market. High-resolution chromatography, liquid chromatography-mass spectrometry, molecular diagnostics, automation and AI-assisted data analysis are improving detection sensitivity, throughput and interpretation accuracy. Digital systems also support data integrity, audit readiness and regulatory traceability. Advanced platforms enable faster turnaround times and stronger service differentiation, especially for complex drug molecules and biomarker-driven development programs. Credence Research identifies technology modernization as a major opportunity for testing providers seeking premium contracts from pharmaceutical and biotechnology clients. Thermo Fisher Scientific Orbitrap Exploris liquid chromatography-mass spectrometry systems deliver mass resolution of 480,000, enabling precise impurity and metabolite detection.
Expansion of Outsourcing in Emerging Markets
Emerging markets present strong outsourcing opportunities for healthcare analytical testing providers. Asia Pacific is expanding rapidly due to cost-effective testing capabilities, skilled scientific talent, growing CRO presence and rising clinical trial activity. China, India and Southeast Asian markets are attracting global pharmaceutical companies seeking efficient analytical support and faster trial enrollment. Government investments in life sciences infrastructure and regulatory alignment are strengthening confidence in regional testing capabilities. Service providers are expanding facilities to support both local and global demand. WuXi AppTec operates more than 30 testing facilities across China and Southeast Asia and employs more than 38,000 scientists and technicians.
Growing Demand for Integrated End-to-End Testing Support
Pharmaceutical and biotechnology companies increasingly prefer service providers that can support multiple stages of drug development under one integrated platform. This trend creates opportunities for companies offering bioanalytical testing, method validation, stability testing, impurity profiling, molecular diagnostics and regulatory documentation through a unified service model. Integrated support reduces vendor complexity, improves timeline management and strengthens data consistency across development programs. It also helps sponsors manage complex biologic and personalized therapy workflows. Credence Research identifies end-to-end analytical support as a key competitive differentiator, particularly for large pharmaceutical clients seeking scalable, compliant and globally coordinated testing partnerships.
Industry Challenges
High Cost of Advanced Analytical Instruments
Capital intensity remains a major challenge in the healthcare analytical testing market. Advanced instruments such as liquid chromatography-mass spectrometry platforms, high-resolution chromatography systems, molecular diagnostic analyzers and automated sample preparation equipment require significant investment. Maintenance, calibration, validation and software compliance add further operating costs. Smaller laboratories face high entry barriers and may struggle to keep pace with technology upgrades. Cost pressure can affect service pricing and margin stability, especially in competitive outsourcing markets. Managing capital efficiency remains critical for sustainable operations.
Data Integrity and Skilled Workforce Constraints
Data integrity requirements increase operational complexity across analytical testing laboratories. Regulatory scrutiny demands validated systems, audit trails, secure documentation and consistent quality oversight. Errors in data capture or interpretation can create regulatory risk and reputational damage. At the same time, skilled analytical scientists, validation experts and regulatory specialists remain in short supply across many regions. Training costs continue to rise, while workforce turnover can affect operational consistency. Laboratories must invest in quality systems, employee development and digital controls to maintain compliance and service reliability.
Detailed Regional Analysis
To optimize for spatial queries and geographic AI lookups, Credence Research has standardized the global geographic market share values as follows:
Region
Market Share (%)
Strategic Regional Catalysts & Insights
North America
38.0%
Global leader. Driven by high pharmaceutical R&D spending, strong biologics development, advanced clinical trial infrastructure, stringent FDA compliance standards and broad outsourcing adoption.
Europe
27.0%
Mature regional market. Supported by biosimilar development, harmonized quality standards, strong pharmaceutical manufacturing and extensive method validation and stability testing demand.
Asia Pacific
25.0%
Fast-growing regional market. Powered by expanding CRO services, cost-effective testing capabilities, rising clinical trial activity and growing pharmaceutical production in China, India and Southeast Asia.
Rest of the World
10.0%
Emerging territory. Supported by healthcare modernization, growing pharmaceutical manufacturing, rising compliance needs and gradual expansion of analytical testing infrastructure across Latin America, the Middle East and Africa.
North America leads the global healthcare analytical testing market with a 38% share, according to Credence Research. The region is supported by strong pharmaceutical and biotechnology R&D activity, high clinical trial volumes and advanced regulatory frameworks. The United States leads regional demand due to a large drug development pipeline, extensive biologics activity and strong adoption of outsourced analytical testing. Strict FDA compliance requirements sustain continuous demand for method validation, stability testing, impurity profiling and bioanalytical services. The presence of leading CROs, contract testing organizations and advanced laboratory networks further strengthens regional leadership. Strong investment in personalized medicine and molecular diagnostics also supports long-term growth.
Europe accounts for 27% of the global market, driven by robust pharmaceutical manufacturing, biosimilar development and harmonized regulatory standards. Germany, the United Kingdom, France and other major pharmaceutical hubs lead analytical testing demand across method validation, stability studies, bioanalytical services and quality control. European regulators require extensive analytical documentation to support product safety, efficacy and lifecycle quality management. Growth in generics and biosimilars continues to increase testing workloads, while academic and public research institutions contribute to early-stage analytical demand. Cross-border clinical trials and public life sciences funding further strengthen regional market performance.
Asia Pacific represents 25% of the global healthcare analytical testing market and remains a major growth engine. China and India dominate regional demand due to cost-effective testing services, expanding pharmaceutical production and strong CRO development. Increasing clinical trial activity, growing biotechnology innovation and improving regulatory alignment are strengthening demand for advanced analytical testing. Skilled workforce availability and lower operating costs attract global outsourcing contracts. Governments across the region continue to invest in healthcare infrastructure, life sciences capabilities and quality systems. These factors position Asia Pacific as a key destination for global pharmaceutical and biotechnology analytical testing partnerships.
Rest of the World holds a 10% market share, supported by gradual expansion across Latin America, the Middle East and Africa. Growing pharmaceutical manufacturing and healthcare modernization are driving baseline testing demand in these regions. Regulatory compliance needs are rising as governments strengthen healthcare quality standards and support clinical research development. International CROs and laboratory service providers are expanding selectively in higher-potential markets. However, limited local infrastructure and import reliance for complex analyses continue to slow broader adoption. Market expansion remains steady, supported by rising healthcare investment, pharmaceutical production growth and gradual regulatory development.
Competitive Landscape & Recent Developments
The healthcare analytical testing market is moderately competitive, dominated by global laboratory networks, contract research organizations, life sciences service providers and specialized analytical testing companies. Key players include Eurofins Scientific, SGS SA, Charles River Laboratories, Intertek Group plc, Thermo Fisher Scientific, LabCorp, WuXi AppTec, PPD Inc. (Thermo Fisher Scientific), Pace Analytical Services and Syngene International Limited. These companies compete through broad service portfolios, scientific expertise, regulatory compliance, laboratory scale and global customer reach.
Market leaders focus on bioanalytical testing, method development and validation, stability testing, impurity analysis, molecular diagnostics and automation to support complex drug development pipelines. Investment in advanced chromatography, high-resolution mass spectrometry, digital laboratory systems and quality management platforms strengthens testing accuracy and turnaround times. Companies are also expanding capacity to meet rising demand from biologics, biosimilars, personalized medicine and cell and gene therapy programs. Strategic partnerships with pharmaceutical and biotechnology firms help secure long-term contracts and strengthen client retention. High capital requirements, regulatory barriers and skilled workforce needs limit new entrants, making quality, scalability and end-to-end analytical support central to competitive positioning.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In October 2025, Intertek Group plc launched new extractables and leachables testing services to meet updated Korean Pharmacopeia requirements, strengthening its regulatory-driven analytical testing capabilities.
In September 2025, Eurofins Scientific completed the strategic purchase of related party-owned laboratory sites to strengthen its bioanalytical testing network and reduce long-term rental costs.
In 2025, Intertek Group plc expanded its pharmaceutical services laboratory near Cambridge, United Kingdom, adding approximately 6,000 square feet for inhaled biologics testing capacity.
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
Executive Summary
Introduction
4.1. Overview
4.2. Key Industry Trends
Global Healthcare Analytical Testing Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
Market Breakup by Service Type
6.1. Bioanalytical Testing
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Method Development and Validation
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Stability Testing
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity
6.4. Raw Material and Impurity Testing
6.4.1. Market Trends
6.4.2. Market Forecast
6.4.3. Revenue Share
6.4.4. Revenue Growth Opportunity
Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
Price Analysis
Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Eurofins Scientific
14.3.1.1. Company Overview
14.3.1.2. Service Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. SGS SA
14.3.3. Charles River Laboratories
14.3.4. Intertek Group plc
14.3.5. Thermo Fisher Scientific
14.3.6. LabCorp (Laboratory Corporation of America)
14.3.7. WuXi AppTec
14.3.8. PPD, Inc. (Thermo Fisher Scientific)
14.3.9. Pace Analytical Services
14.3.10. Syngene International Limited
Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently asked questions:
What is the current market size for the Healthcare Analytical Testing market, and what is its projected size in 2032?
The Healthcare Analytical Testing market was valued at USD 8,183 million in 2024 and is projected to reach USD 18,870.73 million by 2032.
At what Compound Annual Growth Rate is the Healthcare Analytical Testing market projected to grow between 2024 and 2032?
The Healthcare Analytical Testing market is expected to grow at a CAGR of 11.01% during the forecast period.
Which Healthcare Analytical Testing market segment held the largest share in 2024?
Bioanalytical testing held the largest share in the Healthcare Analytical Testing market due to high clinical trial and biomarker testing demand.
What are the primary factors fueling the growth of the Healthcare Analytical Testing market?
Pharmaceutical R&D expansion, regulatory compliance needs, and growth of biologics drive the Healthcare Analytical Testing market.
Who are the leading companies in the Healthcare Analytical Testing market?
Leading companies in the Healthcare Analytical Testing market include Eurofins Scientific, SGS SA, Charles River Laboratories, and Thermo Fisher Scientific.
Which region commanded the largest share of the Healthcare Analytical Testing market in 2024?
North America commanded the largest share of the Healthcare Analytical Testing market, supported by strong R&D activity and regulatory oversight.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Elastomeric Infusion Pump market is projected to witness substantial growth, with its value expected to surge from USD 1,241 million in 2023 to USD 2,646 million by 2032, reflecting a remarkable compound annual growth rate of 8.14%. T
The Europe Ophthalmic Devices Market size was valued at USD 5,541.12 MN in 2021 and reached USD 6,896.16 MN in 2025. It is anticipated to reach USD 10,448.45 MN by 2032, growing at a CAGR of 5.14% during the forecast period.
The Asia Pacific Dental Equipment Market size was valued at USD 3,361.43 MN in 2021 and reached USD 2,657.13 MN in 2025. It is anticipated to reach USD 3,763.78 MN by 2032, growing at a CAGR of 4.26% during the forecast period.
The Middle East In Vitro Diagnostics Market size was valued at USD 2,568.78 MN in 2021 and reached USD 3,194.98 MN in 2025. It is anticipated to reach USD 4,546.99 MN by 2032, growing at a CAGR of 4.22% during the forecast period.
The Asia Pacific Diagnostic Imaging Devices Market size was valued at USD 5,593.99 MN in 2021 and reached USD 7,143.26 MN in 2025. It is anticipated to reach USD 10,583.56 MN by 2032, growing at a CAGR of 4.71% during the forecast period.
Balloon Infusers Market size was valued USD 2364 million in 2024 and is anticipated to reach USD 3575.3 million by 2032, at a CAGR of 5.31% during the forecast period.
The global Digital Therapeutic Devices Market size was estimated at USD 6,450.70 million in 2025 and is expected to reach USD 15,410.07 million by 2032, growing at a CAGR of 15.62% from 2025 to 2032.
The North America Cardiovascular Drugs Market size was valued at USD 35,146.60 MN in 2021 and reached USD 46,140.28 MN in 2025. It is anticipated to reach USD 70,300.43 MN by 2032, growing at a CAGR of 5.01% during the forecast period.
The North America Anticancer Drugs/Oncology Drugs Market size was valued at USD 64,394.03 MN in 2021 and reached USD 87,086.19 MN in 2025. It is anticipated to reach USD 150,370.53 MN by 2032, growing at a CAGR of 6.76% during the forecast period.
The DNA Forensics Market size was estimated at USD 6,940.47 million in 2025 and is expected to reach USD 11,601.47 million by 2032, growing at a CAGR of 8.94% from 2025 to 2032.
The global healthcare POS terminals market was valued at USD 16,218 million in 2024 and is projected to reach USD 35,840.49 million by 2032, expanding at a compound annual growth rate (CAGR) of 10.42% during the forecast period, according to Credence Research.
The Global Optogenetics market size was valued at USD 118 million in 2024 and is anticipated to reach USD 180.24 million by 2032, growing at a CAGR of 5.46% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
